ファインデックス（3649） – Strategic Alliance with Toyota Tsusho Corporation

Company name: Name of representative: Inquiries: May 6, 2022 FINDEX Inc Teruo Aibara, President & CEO (Securities code: 3649; PRIME Market) Atsushi Fujita, Director and Head of Administration (Telephone: +81-89-947-3388) Strategic Alliance with Toyota Tsusho Corporation At an extraordinary meeting of the Board of Directors held on May 6, 2022, the Company resolved to enter into a strategic partnership agreement with Toyota Tsusho Corporation ((hereafter referred to as “Toyota Tsusho”) regarding medical information system business and health tech business and entered into the agreement on the same date. 1. Reason for Alliance With our goal of “Toward better health and wellbeing of all people” we have delivered a lot of healthcare organizations with integrated digital solutions, which realize their centralized management and effective utilization of test data and document data. Also, leveraging our nurtured technology and trust, we, ourself, invented, developed, manufactured, and sold gaze analyzing perimeter which adopts a completely new testing principle. Towards better society, at such a momentous time, we are committed to improve the convenience and efficiency of medical exam at healthcare organizations overseas, as well as early detection of optical diseases, and educational activities in Japan, in collaboration with Toyota Tsusho, who has built up relationships of trust through their wide variety of businesses around the world. 2. Area for Alliance solutions. The Company and Toyota Tsusho will cooperate under an exclusive sales agreement mainly for the following (i) Overseas sales of medical information solutions As the geographical strategies, we will sell medical information platform, mainly our flagship product “Claio” (image filing system), to key healthcare organizations in India and the ASEAN region. We will establish a cordial support system in collaboration with local medical system companies to ensure efficient and sustainable delivery of our product and service. In June 2022, we will introduce Claio, on a trial basis, to Sakra World Hospital in India, which Toyota Tsusho has its investment stake, and begin test operations. With a population of over 1.3 billion, the healthcare market of India has an unprecedented scalability, and at the same time, there remain a lot of issues that can be ameliorated by digitalization. Addressing challenges to solve issues out there, we will contribute to the realization of a sustainable society by improving the quality of medical care and the efficiency of hospital management. (ii) Introduction of “GAP-screener” (gaze analyzing perimeter/regulatory product) to health checkup facilities in Japan GAP-screener”, which was commercialized for optional use during health checkups, will be introduced to domestic health checkup facilities and multiphasic health screening facilities under Toyota Tsusho’s sales strategy. This product is our original invention, darkroom-free, objective optical testing device. By permanently exhibiting this solution other than ophthalmology facilities, more convenient testing will be enabled, leading to the early detection of glaucoma. We will also utilize the visual field data obtained through the test, for various possibilities in future research and development in the medical field, such as the establishment of new treatment methods. 1 3. Corporate Profile of Strategic Alliance Partner Toyota Tsusho Corporation 9-8, Meieki 4-chome, Nakamura-ku, Nagoya Ichiro Kashitani General trading and business investment company, engaged in metal, parts and logistics, automotive, machinery, energy and project, chemical and electronics, food and consumer services, etc. 64,936 million yen July 1, 1948 TOYOTA MOTOR CORPORATION 21.69％ The Master Trust Bank of Japan, Ltd. (Trust Account) 13.56％ TOYOTA INDUSTRIES CORPORATION 11.18％ (As of September 30, 2021) Capital, human, transaction, related parties N/A ⑧ Relationship with our Group ⑨ Recent three-year performance and financial status Fiscal year 2019 2020 (JPY in 100 million） 2021 Corporate Name① ② Location (head office) ③ President & CEO ④ Business ⑤ Capital ⑥ Establishment ⑦ Major Shareholders Total asset Net asset Gross profit Operating income Income before tax Net income EPS (JPY) DOE (JPY) 44,414 13,896 6,384 2,151 2,291 1,326 376.89 100 45,452 13,724 6,398 2,103 2,248 1,355 385.25 110 52,280 16,580 6,076 2,130 2,214 1,346 382.56 112 4. Schedule Date of resolution at Board of Director：May 6, 2022 Date of alliance agreement：May 6, 2022 Date of the commencement of business：May 6, 2022 5. Outlook The impact of this strategic alliance on our performance is currently under inspection, we believe that this alliance will significantly contribute to our corporate value enhancement in the medium to long term. In a timely manner, we will appropriately announce any matters that should be disclosed. 2